China SXT Pharmaceuticals, Inc. (SXTC) shareholders
SXTCNasdaqPharmaceutical PreparationsFiscal year ends March 31
Số liệu tài chính tới năm tài chính 2026, năm kết thúc ngày Mar 31, 2026Last filing: 20-F on Jul 1, 2026Score 4/30
$2.86−0.13 (-4.35%)
Close on Nov 17, 2026Market cap $2.74MP/E –Yield –
Ownership
Institutional holdings as of Mar 31, 2026, from 13F filings
Held by institutions
0.0%
0M of 1M shares
Institutional holders
0
0 new, 8 sold out
Net institutional buying
-0M
In Q1 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Foong Soon Hong, Randy | 10,588,240 | 9.12% | 13G (passive) | Jul 29, 2025 |
| Tan Soo Seng | 10,392,160 | 8.95% | 13G (passive) | Jul 29, 2025 |
| Tan Cheng Guan | 10,196,080 | 8.79% | 13G (passive) | Jul 29, 2025 |
| Ching Choon Hwa | 9,803,920 | 8.45% | 13G (passive) | Jul 29, 2025 |
| Orca Capital AG | 1,112,788 | 9.90% | 13G (passive) | Oct 8, 2026 |
Top institutional holders
13F holdings as of Dec 31, 2025
| Holder | Shares | % of SXTC | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Citadel Advisors LLC | 13 | 0.00% | $240.92K | +9 | 0.00% |
| Invesco Ltd. | 7 | 0.00% | $136.53K | – | 0.00% |
| Geode Capital Management, LLC | 4 | 0.00% | $85.87K | – | 0.00% |
| XTX Topco Ltd | 2 | 0.00% | $36.44K | New | 0.00% |
| Virtu Financial LLC | 1 | 0.00% | $20.00K | −1 | 0.00% |
| Tower Research Capital LLC (TRC) | 0 | 0.00% | $2.92K | – | 0.00% |
| Royal Bank of Canada | 0 | 0.00% | $1.00K | New | 0.00% |
| UBS Group AG | 0 | 0.00% | $356 | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q1 2026 | 0 | 0M | 0.0% | 0 / 0 | 0 / 8 | 0M | 0M |
| Q4 2025 | 8 | 0M | 0.0% | 2 / 1 | 1 / 4 | 0M | 0M |
| Q3 2025 | 10 | 0M | 0.0% | 7 / 1 | 1 / 1 | 0M | 0M |
| Q2 2025 | 4 | 0M | 0.0% | 2 / 1 | 0 / 0 | 0M | 0M |
| Q1 2025 | 2 | 0M | 0.0% | 2 / 0 | 0 / 0 | 0M | 0M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Feng Felix Zhou | Co-CEO and Director | 4 | 0.00% | Apr 27, 2026 |
| Xiaodong Sean Pan | Chief Financial Officer | – | – | Apr 27, 2026 |
| Lim Sze Beng Simon | Co-Chief Executive Officer | – | – | Apr 27, 2026 |
| Jun Zheng | Director | – | – | Apr 27, 2026 |
| Tong Tony Liu | Director | – | – | Apr 27, 2026 |
| Yong Lip Chee | Director | – | – | Apr 27, 2026 |
| Xiaodong Ji | Director | – | – | Apr 27, 2026 |
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
2.95%
0M shares short
Days to cover
1.0
At 1M shares a day
Change since last report
-96.1%
From 1M shares
Short volume, 20 days
60.3%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of China SXT Pharmaceuticals's stock actually held short. Settlement fails (shares not delivered on time) peaked at 17,243,334 shares on Oct 13, 2026 over the last 90 days.
See a number that looks wrong?